nitabosco, you write: "The CEO and CMO of the company receive 3.5% and 1.3% of the enterprise value of a buyout..."
I know you're right about this but can you source this for me please?
The appointment of Yacoub Habib Ph.D. to lead the company's partnering and licensing initiatives is interesting in that it indicates Trevena's willingness to look at further partnering beyond 027 that might include its pain portfolio while simultaneously retaining the migraine asset.
Nimble and smart.
cherryhilljoe, being "above a buck" is a NASDAQ requirement and isn't the issue for the NYSE or NovaBay. The issue has to do with operating capital requirements. Those aren't as easily fixed but are another set of issues altogether.
biotechdd ~ I won't! The second Phase 3 results could come in by the end of the week but no later than mid-July. They'll no doubt be as good. GLTA
Sentiment: Strong Buy
Plecanatide blows them all away. Diarrhea rates not only below 10 but at 6. And all while passing the most stringent requirement in Phase 3 history for a CIC drug. Amazing!!!!!!!!!!!!!!!!!
This does concern me. Sunesis delayed sharing the Valor study results allowing large blocks of shares to be sold as they planned and executed their recovery strategy. Meanwhile, message board participants made excuses for all the selling similar to what's happening here.
The difference here is that I knew Valor was a loser a month before results were released. Here, I'm fighting back bad feelings because I'm still hopeful that results will be good. Still...
Well, IRDW may have in some alternate universe, but Ironwood (IRWD) was down only 4% in the past 2 days and considerably less in the past 3...that says absolutely nothing
The lack of institutional ownership is disconcerting. In this instance, however, it doesn't say anything bad about Plecanatide or the company, but rather, speaks to the uncertainty surrounding the treatment space.
This question is relatively easy to answer. They both have to work. That said, a stumble in one dosage in one trial is acceptable if the other trial reads out successfully in that same dosage group and the cumulative numbers between the two trials are statistically significant.
Diarrhea rates under 20% are good enough, however, I think we're going to see something right around 12-13%.
rizzle6969 ~ I think that's a very fair assessment of the situation punctuated by the even split of thumbs up to thumbs down. I've always thought that a 4 or 5 mg dose would have been a better choice in that it would have predictably fallen closer to the larger 3 mg data set.
There's more misinformation circulated by more people on this board than any I have yet encountered.
No one is "walking it down". Rather, all bets have been placed. Some are taking chips off the table while others are adding. Now that management has their shares data comes soon. And we see what unfolds.